BioConsortia Raises $15 Million to Scale Microbial Nitrogen-Fixing Seed Treatment
19 October 2026, California: BioConsortia, an agricultural biologicals company based in Davis, California, has raised $15 million in new equity funding to speed the commercial rollout of two seed treatment products built from naturally occurring soil microbes, the company said on October 9. The investment came from an entity affiliated with John Pasquesi, managing member of Otter Capital, which was already a BioConsortia investor.
The money is earmarked for manufacturing, regulatory approvals and sales infrastructure needed to launch the products widely, as well as to keep funding a broader pipeline of biological fungicides, nematicides and insecticides still in development with partners.
BioConsortia’s two lead products sit in a category called biologicals: crop inputs derived from living organisms, such as bacteria or fungi, rather than synthetic chemistry. The first, called Always N, is a nitrogen-fixing seed treatment. Certain soil bacteria can pull nitrogen gas from the air and convert it into a form plants can use, a process called biological nitrogen fixation that normally occurs in legume crops such as soybeans and peas through root nodules. BioConsortia’s version is applied as a coating on seed and is designed to work in non-legume row crops as well, reducing how much synthetic nitrogen fertilizer a farmer needs to apply. The company sells both a conventionally bred, wild-type version of the microbe and a gene-edited version, giving it flexibility across countries with different rules on gene-edited organisms.
The second product, Zaffre, is a biostimulant, a treatment meant to help a crop perform better under stress rather than supply a nutrient directly. BioConsortia says Zaffre improves seed emergence and early stand establishment, and helps plants cope with cold or heat stress during germination.
Trial results and early market uptake
The company says Zaffre produced an average yield gain of 4.4 bushels per acre across three seasons of corn trials, a company-reported figure rather than an independently audited one, but consistent across multiple growing seasons rather than a single trial.
For Always N, BioConsortia pointed to real-world adoption data from New Zealand, where it works with a distribution partner called H&T. There, the share of treated seed using Always N rose from about 5 percent in 2024 to about 50 percent in 2025, and the company is projecting around 80 percent for 2026, though that last figure is a forecast rather than a confirmed result. BioConsortia also says Always N has a shelf life of more than two years before it is applied to seed, plus a further two years once it has been coated onto seed, which matters commercially because it means the product can sit in a normal seed-treatment supply chain without losing effectiveness, rather than needing to be used almost immediately like some living microbial products.
Commercially, BioConsortia has a partnership with The Mosaic Company covering distribution of its seed treatments across the Americas, and is working with Nichino on a foliar biofungicide, a product sprayed on crop leaves rather than applied to seed, in select markets. The company says it is also running expanded trials with other partners on biological nematicides and insecticides, and is pushing into the European Union, Asia and Australia in addition to its existing footprint in the Americas and New Zealand.
BioConsortia’s chief executive, Marcus Meadows-Smith, said the new funding builds on the company’s existing patent portfolio and commercial foundation, a characterization echoed by Pasquesi in the funding announcement.
Also Read: USDA Reports Record Soybean Yield, Bigger Corn Crop in October Forecast
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com
